The U.S. Food and Drug Administration (FDA) has given its approval to Valneva’s single-shot vaccine, known as Ixchiq, for individuals aged 18 and older who face an increased risk of exposure to the chikungunya virus.

• This approval marks a significant milestone as it’s the first preventive shot to combat this mosquito-borne disease in the United States. 
• The chikungunya virus is primarily transmitted to people through mosquito bites. Common symptoms of infection include fever and joint pain, with additional possible symptoms like headaches, muscle pain, joint swelling, or a rash. 
• As of now, there is no official word from Valneva regarding the availability of the Ixchiq vaccine in the United States. It’s essential to await their response for further information on distribution.